JAMA Netw Open

Can statin use mitigate VTE risk in patients on hormone therapy?

December 20, 2023

According to this case-control study, statin therapy was associated with reduced risk of VTE in women taking hormone therapy (HT), with greater risk reduction seen with high-intensity statins. The findings suggest that statins may reduce VTE risk in women exposed to HT and that HT may not be contraindicated in women taking statins.

• This nested case-control study analyzed data from a commercially insured claims database in the U.S.
• Eligible participants included women ages 50 to 64 years; data analysis occurred from January 2022 to August 2023.
• The total sample of 223,949 individuals (mean age, 57.5 years) included 20,359 cases and 203,590 matched controls.
• Of the entire sample, 19,558 individuals (8.73%) had recent HT exposure and 36,238 individuals (16.18%) had current statin exposure.
• In adjusted models, individuals with any recent HT exposure had greater odds of VTE compared with those with no recent HT exposure (odds ratio [OR], 1.51; 95% confidence interval [CI], 1.43-1.60).
• Individuals receiving current statin therapy had lower odds of VTE compared with those with no current statin exposure (OR, 0.88; 95% CI, 0.84-0.93).
• When compared with those not recently taking HT or statins, the odds of VTE were greater for those taking HT without statins (OR, 1.53; 95% CI, 1.44-1.63) and for those taking HT with statins (OR, 1.25; 95% CI, 1.10-1.43), but were lower for those taking statins without HT (OR, 0.89; 95% CI, 0.85-0.94).
• Individuals taking HT with statin therapy had 18% lower odds of VTE than those taking HT without statins (OR, 0.82; 95% CI, 0.71-0.94) and there was greater risk reduction with higher intensity statins.

Source:

Davis JW, et al. (2023, December 1). JAMA Netw Open. Statin Use and the Risk of Venous Thromboembolism in Women Taking Hormone Therapy. https://pubmed.ncbi.nlm.nih.gov/38100102/